within Pharmacolibrary.Drugs.N_NervousSystem.N07B_DrugsUsedInAddictiveDisorders.N07BC04_Lofexidine;

model Lofexidine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.72,
    Cl = 8.333333333333334e-06,
    adminDuration = 600,
    adminMass = 0.2 / 1000000,
    adminCount = 1,
    Vd = 0.0015,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.018333333333333333,
    Tlag = 10.200000000000001);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Lofexidine</td></tr><tr><td>ATC code:</td><td>N07BC04</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>0.2</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>30</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Lofexidine is a centrally acting alpha-2 adrenergic receptor agonist used primarily to manage symptoms of opioid withdrawal. It reduces the release of norepinephrine and is approved for clinical use in opioid detoxification. Lofexidine is currently approved in several countries, including the United States and the United Kingdom, for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following single oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N07BC04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Lofexidine;
